Cryoport, Inc. (NASDAQ:CYRX) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Cryoport, Inc. (NASDAQ:CYRX) have been assigned a consensus rating of “Moderate Buy” from the seven research firms that are covering the company, Marketbeat Ratings reports. Three investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $12.29.

CYRX has been the subject of several analyst reports. Needham & Company LLC restated a “buy” rating and set a $11.00 price target on shares of Cryoport in a report on Friday, January 17th. UBS Group lifted their target price on shares of Cryoport from $7.00 to $9.00 and gave the stock a “neutral” rating in a report on Friday, October 18th. Guggenheim began coverage on shares of Cryoport in a report on Thursday, December 19th. They set a “buy” rating and a $11.00 price target on the stock. Finally, Roth Mkm decreased their price objective on shares of Cryoport from $18.00 to $15.00 and set a “buy” rating for the company in a report on Friday, November 8th.

Cryoport Trading Down 3.7 %

NASDAQ:CYRX opened at $8.01 on Wednesday. The company has a 50-day moving average price of $7.74 and a 200-day moving average price of $7.95. The stock has a market cap of $395.93 million, a price-to-earnings ratio of -2.37 and a beta of 1.58. The company has a current ratio of 5.70, a quick ratio of 5.32 and a debt-to-equity ratio of 0.48. Cryoport has a 12 month low of $5.32 and a 12 month high of $20.10.

Cryoport (NASDAQ:CYRX) last issued its quarterly earnings results on Thursday, November 7th. The company reported ($0.02) earnings per share for the quarter, topping the consensus estimate of ($0.25) by $0.23. Cryoport had a negative return on equity of 13.35% and a negative net margin of 70.08%. The company had revenue of $56.66 million for the quarter, compared to analysts’ expectations of $58.13 million. During the same period in the prior year, the firm earned ($0.31) earnings per share. Equities analysts predict that Cryoport will post -0.99 EPS for the current year.

Insiders Place Their Bets

In other Cryoport news, Director Ramkumar Mandalam sold 7,369 shares of Cryoport stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $7.46, for a total transaction of $54,972.74. Following the completion of the sale, the director now directly owns 59,497 shares of the company’s stock, valued at $443,847.62. The trade was a 11.02 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Jerrell Shelton sold 50,000 shares of Cryoport stock in a transaction dated Thursday, November 21st. The shares were sold at an average price of $6.51, for a total value of $325,500.00. Following the completion of the sale, the chief executive officer now owns 731,897 shares of the company’s stock, valued at $4,764,649.47. The trade was a 6.39 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 109,869 shares of company stock worth $735,673 over the last quarter. Company insiders own 10.10% of the company’s stock.

Institutional Investors Weigh In On Cryoport

Several institutional investors have recently bought and sold shares of CYRX. Avanza Fonder AB acquired a new position in Cryoport in the 4th quarter worth approximately $64,000. Dynamic Technology Lab Private Ltd purchased a new stake in shares of Cryoport in the 3rd quarter valued at $82,000. Intech Investment Management LLC acquired a new stake in shares of Cryoport in the third quarter worth $105,000. Hsbc Holdings PLC purchased a new position in shares of Cryoport during the second quarter worth $92,000. Finally, The Manufacturers Life Insurance Company lifted its position in Cryoport by 9.5% during the second quarter. The Manufacturers Life Insurance Company now owns 17,683 shares of the company’s stock valued at $122,000 after purchasing an additional 1,534 shares during the period. 92.90% of the stock is currently owned by institutional investors and hedge funds.

Cryoport Company Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.